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OBJECTIVEdElevated plasma interleukin-18 (IL-18) has been linked to onset of diabetes
mellitus (DM) and its complications. However, so far this association has been shown only in
predominantly white populations. We examined IL-18 levels and their association with incident
DM in a racially heterogeneous population.
RESEARCH DESIGN AND METHODSdIn a nested case-cohort design representing a
9-year follow-up of 9,740 middle-aged, initially healthy, nondiabetic white and African Amer-
ican participants of the Atherosclerosis Risk in Communities Study, we selected and measured
analytes on race-stratified (50% white, 50% African American) random samples of both cases of
incident diabetes (n = 548) and eligible members of the full cohort (n = 536).
RESULTSdBaseline IL-18 levels were significantly higher in white participants comparedwith
African American participants (P , 0.001). Although white participants in the fourth (versus
first) quartile of IL-18 levels had a significant hazard ratio (HR) for developing DM (HR: 2.1, 95%
CI: 1.3–3.4), after adjustment for age, sex, and study center, no difference was seen among
African Americans (HR: 1.0, 95% CI: 0.6–1.7). Unlike those in African Americans, IL-18 levels
in whites had a significant correlation with age (P, 0.01); anthropometric characteristics such as
waist circumference (P, 0.001), height (P = 0.04), waist-to-hip ratio (P, 0.001), and BMI (P,
0.01); and total (P , 0.001) and high-molecular-weight (P , 0.001) adiponectin.
CONCLUSIONSdThere are racial differences in levels of IL-18 and the association of IL-18
with risk factors and incident type 2 DM. In addition, there seems to be a complex interplay of
inflammation and adiposity in the development of DM.
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D iabetes and its complications lead toan enormous disease burden. It hasbeen estimated that 366 million
people worldwide will develop diabetes by
the year 2030 (1). Studies have shown that
parental history of diabetes, anthropometric
measures, and systolic blood pressure
(SBP), alone or combined with simple
laboratory measures including fasting glu-
cose and lipid parameters, can characterize
the risk for diabetes inmiddle-aged adults
(2). In addition, there is growing evidence
to suggest that insulin resistance and di-
abetes are associated with chronic inflam-
mation (3,4). Several proinflammatory
cytokines are found to be elevated in
diabetes and its complications (5). In
contrast, anti-inflammatory molecules like
adipocytokines have been consistently
lower in individuals with diabetes and
metabolic syndrome (6,7), a finding that
indicates their protective role in the patho-
genesis of diabetes. However, the exact
pathological mechanisms underlying these
inflammatory and anti-inflammatory path-
ways are largely unknown.
Interleukin-18 (IL-18) is a cytokine
that is produced constitutively in several
different cells in the body including macro-
phages, endothelial cells, vascular smooth
muscle cells, dendritic cells, and Kupffer
cells, aswell as adipocytes (8). It is expressed
as an inactive precursor molecule that is
cleaved by the enzyme caspase-1 (9). IL-
18 is proinflammatory and enhances matu-
ration of T cells and natural killer cells and
promotes production and release of other
cytokines, chemokines, and adhesion mol-
ecules (9). IL-18 induces the production of
tumor necrosis factor (TNF)-a, which in
turn promotes the synthesis and release of
IL-6 and C-reactive protein (CRP) (10).
Elevated levels of IL-18 have been
associated with obesity, metabolic syn-
drome, insulin resistance, dyslipidemia,
and atherosclerosis (11,12). Recently,
two studies have shown that elevated levels
of IL-18 are associated with higher risk
of diabetes (13,14). Both of these studies
looked at populations of European de-
scent. It is unknown if a similar association
exists for other ethnicities. In a study in-
volving the Atherosclerosis Risk in Com-
munities Study (ARIC) cohort, Duncan
et al. (4) showed that low-grade inflamma-
tion was associated with onset of diabetes.
However, the authors noted that although
an inflammation score was robustly asso-
ciated with onset of diabetes in whites, no
association was found in the African
American population. They postulated
that not all sources of low-grade systemic
inflammatory states increase the risk of de-
veloping diabetes.
With this background, we aimed to
determine whether elevated levels of IL-18
were associated with incident diabetes,
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independent of traditional risk factors, in a
heterogeneous population such as the
ARIC cohort and whether racial differ-




ARIC is a population-based study involv-
ing both whites and African Americans
aged 45–64 years in four U.S. communities
in North Carolina, Mississippi, Minnesota,
and Maryland (15). Between 1987 and
1989, 15,792 men and women were
recruited and attended a baseline exam
(visit 1). Cohort members attended three
subsequent clinic visits at ;3-year inter-
vals (visits 2–4). Human subject research
review committees at the involved insti-
tutions approved the study, and all par-
ticipants gave written informed consent.
A stratified, nested case-cohort design was
used in an ancillary study investigating
inflammatory precursors of diabetes. This
design has been used to investigate the role
of total and high-molecular-weight (HMW)
adiponectin, leptin, ferritin, free fatty acids,
and other plasma biomarkers in the de-
velopment of diabetes in the ARIC study
(4,6,15–17).
From the baseline cohort, we excluded
2,018 participants with prevalent diabetes,
95 members of ethnic groups other than
African Americans or whites, 853 partici-
pants not returning for any follow-up visit,
26 with no valid diabetes determination at
follow-up, 6 with restrictions on stored
plasma use, 12 with missing baseline an-
thropometric data, 2,514 participants in
previous ARIC case-control and case-
cohort studies involving cardiovascular
disease for whom stored plasma was either
previously exhausted or held in reserve,
212 for incomplete fasting (,8 h), and 316
with missing information for hypertension
and inflammation markers. A final sam-
pling frame of 9,740 individuals (71% of
those in the full cohort without diabetes at
baseline) was established after exclusions.
Of these, 1,105 participants (11.3% of the
final sample) were ascertained to have in-
cident diabetes during follow-up. From the
eligiblemembers of this baseline cohort, we
selected and measured analytes on ethnic-
ity-stratified (50% white, 50% African
American) random samples of both cases
of incident diabetes and eligible members
of the full cohort (1,095 individuals in
total). Some participants within the co-
hort random sample developed diabetes
during follow-up and were part of the
case random sample as well.We excluded
an additional 11 participants who had
missing values for IL-18, leaving a total
of 1,084 subjects for analysis.
Data collection
Baseline clinical and demographic data,
including parental history of diabetes,
were recorded. We defined parental his-
tory of diabetes as a report of diabetes in
either parent. The definitions and methods
for baseline measurements (height, weight,
SBP, hypertension, triglycerides [TGs],
HDL cholesterol [HDL-C], inflammation
markers, and adipocytokines) have been
previously described (4,6). A score was
computed to indicate low-grade systemic
inflammation, ranging from 0 to 6; one
point was attributed to a value greater
than themedian of the cohort randomsam-
ple for each of the six markers of systemic
inflammation: IL-6, CRP, orosomucoid, si-
alic acid, white blood cell (WBC) count,
and fibrinogen (4). Glucose was measured
at baseline and at follow-up visits by stan-
dard hexokinase method.
Anthropometric measures were ob-
tained at baseline visit. BMI was com-
puted using the formula weight/height2.
Smoking was assessed as a binary variable
with 0 = never or former smokers and 1 =
current smokers. Sport and physical ac-
tivity was assessed with semicontinuous
indices created from individual compo-
nent questions described in detail else-
where (18). The index ranged from 1
(low) to 5 (high). For education, we used
a four-level categorical variable: 1, no high
school diploma or less; 2, high school or
some college; 3, beyond bachelors; and 4,
missing data.
Diagnosis of incident diabetes
Cases of incident diabetes were defined
on the basis of: 1) a reported physician
diagnosis, 2) reported use of antidiabetic
medications during the 2 weeks prior to
the visit, or 3) a fasting ($8 h) glucose
value of at least 7.0 mmol/L. The date of
diabetes incidence was estimated by linear
interpolation using glucose values at the
ascertaining visit and the previous visit
(4,6).
Measurement of IL-18 levels
Circulating levels of IL-18 were measured
in a centralized laboratory in plasma sam-
ples thatwere continuously stored at2708C
prior to analysis. All measurements were
performed in duplicate using a sandwich
ELISA according to manufacturer’s proto-
col (R&D Systems, Minneapolis, MN). The
intra- and interassay coefficients of variance
were 5.4 and 12.5%, respectively. The re-
liability coefficient was 0.98 based on 39
blinded quality control split samples.
Statistical analysis
Weighted analyses were done based on
the case-cohort sampling design to allow
for inference to the entire cohort. Weights
were defined as the inverse of the ethnicity-
specific sampling fractions. Spearman
correlations were calculated to describe
unadjusted associations between IL-18
and baseline covariates. Total and HMW
adiponectin were logarithmically trans-
formed to approximate normality. Quar-
tiles of IL-18 were created from IL-18
distribution in the cohort random sample.
Quartile values were used in the models,
and test of trend was generated across
the quartiles of IL-18. Cox proportional
hazards models were fitted to investigate
the relationship between IL-18 and time to
onset of diabetes. Wald tests of interaction
terms were used to test heterogeneity in the
association between race and IL-18 quar-
tile. All statistical testing was performed
using two-sided tests with P = 0.05 as the
cutoff for statistical significance. Statistical
analyseswere performedusing the SAS (SAS
Institute Inc., Cary, NC) and SUDAAN (Re-
search Triangle Institute, Research Triangle
Park, NC) statistical software packages.
RESULTSdOur case-cohort sample of
1,084 ARIC study participants included
488 (45%) African American and 596
(55%) white individuals. The cohort ran-
dom sample comprised 630 individuals,
and the incident diabetes random sample
included 548 individuals. Of the partici-
pants selected in the cohort randomsample,
94 developed diabetes during follow-up,
and 71 of them were included in the
incident diabetes random sample. Thus,
there were 23 incident diabetes cases in
addition to those in the incident diabetes
sample. Among cases, 146werewhitemen,
142 were white women, 68 were African
American men, and 192 were African
American women. Among noncases, the
corresponding numbers were 113, 195,
68, and 160, respectively. Table 1 shows
overall and ethnicity-specific distribution
of the baseline demographic, clinical, and
biomarker characteristics in this cohort
random sample. Supplementary Table 1
compares the baseline characteristics of
the participants selected in the final sample
with those of the entire cohort, stratified
by ethnicity. Baseline IL-18 levels were sig-
nificantly higher in white compared with
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African American participants (median [in-
terquartile range]; 235.6 [129.7] vs. 190.6
[116.4] pg/mL; P, 0.001). This difference
was seen in both men (P , 0.001) and
women (P, 0.001) (Table 2). A statistically
significant interaction between race and IL-
18 quartile for incident diabetes was found
in the study population after adjusting for
age, sex, and race (P = 0.01). However, after
additional adjustment for parental history
of diabetes, BMI, SBP, andwaist-to-hip ratio
(WHR), the interaction between race and
IL-18 quartile lost significance (P = 0.15).
HRs for developing diabetes by quar-
tiles of IL-18 are shown in Supplementary
Table 2. A statistically significant HR for
developing diabetes was seen for study
participants in the fourth (versus first)
quartile of IL-18 levels (HR: 1.5; 95% CI:
1.1–2.1) in the crude analysis. TheHRs for
fourth versus first quartile remained sig-
nificant even after adjusting for age, sex,
study center, and race (1.7; 1.2–2.3). The
effects were attenuated, and the HR were
no longer statistically significant after se-
quential additional adjustment for parental
history of diabetes, BMI, SBP, and WHR
(1.2; 0.8–1.7); sport index, education level,
and smoking status (0.9; 0.7–1.7); glucose,
HDL-C, and TGs (0.9, 95% CI: 0.6–1.4);
inflammation score (1.0; 0.7–1.5); or total
and HMW adiponectin (1.1; 0.8–1.6)
(Supplementary Table 2).
In a similar subanalysis by race (Table 3),
risk for developing diabetes in the fourth
(versus first) quartile of IL-18 levels was
statistically significant among whites in
the crude analysis (HR: 2.5; 95% CI:
1.6–4.0). This association remained sig-
nificant after adjustment for age, sex, and
study center (2.1; 1.3–3.4). However, stati-
stical significance was lost after additional
adjustment for clinical variables (1.2; 0.7–
2.0) and when adjustments were made for
biochemical and inflammatory markers
and adipocytokines. None of the models
showed a significant association among
African Americans.
Correlations between IL-18 levels and
various baseline demographic, clinical,
biochemical, inflammatory, and anti-
inflammatory variables markedly varied
among thewhites and theAfricanAmericans
in the cohort randomsample (Supplementary
Table3).Unlike those inAfricanAmericans,
IL-18 levels in whites had a significant cor-
relation with age (P , 0.01) and anthro-
pometric characteristics such as waist
circumference (P , 0.001), height (P =
0.04), WHR (P , 0.001), and BMI (P ,
0.01). Similarly, IL-18 levels among
whites were significantly correlated with
SBP (P , 0.01), fasting glucose (P ,
0.001), and insulin (P , 0.001). IL-18
levels among whites showed a highly sig-
nificant correlation with HDL-C (P ,
0.001), LDL cholesterol (LDL-C; P ,
0.001), and TGs (P, 0.001) andmoderate
correlation with oxidized LDL (P = 0.04),
Table 1dBaseline characteristics in participants who developed diabetes and those who did not stratified by race/ethnicity
Characteristic
With diabetes Without diabetes
P value*AA White AA White
Age (years) 52.2 (5.5) 54.1 (5.5) 51.5 (5.1) 52.9 (5.6) ,0.0001
Male (%) 26.2 50.7 29.8 36.7 0.0079
Current smoker (%) 20.4 19.4 26.8 19.2 0.0791
Parental history of diabetes (%) 36.2 33.0 22.8 20.8 0.0631
Education level 1.9 (0.8) 2.1 (0.7) 2.0 (0.8) 2.3 (0.7) 0.0005
Sport index 2.2 (0.6) 2.5 (0.8) 2.1 (0.8) 2.6 (0.8) ,0.0001
Height (cm) 166.9 (9.5) 168.8 (9.0) 167.4 (9.0) 167.3 (9.2) 0.9012
Waist circumference (cm) 105.8 (15.7) 103.9 (12.4) 95.5 (13.7) 93.2 (11.7) 0.0003
BMI (kg/m2) 32.4 (6.7) 30.0 (5.2) 28.7 (5.7) 26.4 (4.2) ,0.0001
WHR 0.9 (0.1) 1.0 (0.1) 0.9 (0.1) 0.9 (0.1) 0.5130
Systolic blood pressure (mmHg) 127.5 (17.6) 122.7 (15.7) 124.9 (18.1) 115.5 (14.5) ,0.0001
Fasting glucose (mg/dL) 107.5 (9.2) 108.4 (9.5) 96.6 (8.6) 97.0 (8.0) 0.0766
Insulin (pmol/L) 137.5 (77.9) 111.8 (68.1) 85.4 (52.0) 61.2 (55.4) ,0.0001
HDL-C (mg/dL) 52.0 (14.5) 43.9 (13.1) 61.1 (18.2) 52.8 (15.7) ,0.0001
LDL-C (mg/dL) 139.4 (44.5) 139.1 (36.5) 132.8 (42.7) 132.2 (36.8) 0.4676
Ox-LDL (units/L) 41.4 (16.5) 43.9 (14.9) 38.2 (13.6) 39.8 (14.0) 0.5547
NEFA (mEq/L) 0.9 (0.5) 0.9 (0.4) 0.8 (0.4) 0.9 (0.4) 0.2093
Total triglycerides (mg/dL) 110.0 (68.0) 137.0 (90.0) 82.0 (47.0) 106.5 (76.5) ,0.0001
WBC (31000/m3) 5.3 (2.4) 6.4 (2.0) 5.1 (2.0) 5.6 (1.9) 0.0001
IL-18 (pg/mL) 198.3 (116.6) 277.4 (123.3) 188.0 (115.5) 234.4 (125.2) ,0.0001
IL-6 (pg/mL) 2.5 (2.0) 2.5 (2.0) 2.2 (1.8) 1.8 (1.5) 0.0006
hsCRP (mg/mL) 3.1 (5.5) 2.4 (3.8) 2.6 (4.0) 1.2 (2.1) ,0.0001
Orosomucoid (mg/dL) 92.4 (20.1) 96.9 (22.5) 87.8 (20.1) 85.7 (19.6) 0.1222
Fibrinogen (mg/dL) 315.9 (68.2) 305.7 (60.5) 309.8 (70.3) 279.1 (52.1) ,0.0001
C3 (mg/dL) 184.2 (53.9) 163.4 (33.0) 163.2 (34.5) 143.8 (31.4) ,0.0001
Fetuin-A (g/mL) 482.4 (117.9) 517.9 (75.1) 465.1 (88.5) 499.9 (76.1) ,0.0001
Sialic acid (mg/dL) 96.9 (25.5) 98.4 (30.3) 92.6 (34.2) 88.0 (29.2) 0.0007
HMW adiponectin (g/mL) 1.2 (1.2) 1.9 (1.6) 1.9 (1.8) 2.9 (2.2) ,0.0001
Total adiponectin (g/mL) 3.7 (2.5) 4.9 (3.1) 5.0 (3.1) 6.9 (3.8) ,0.0001
Data are given as mean (SD) for normally distributed variables, median (interquartile range) for skewed variables, or percentage where indicated. AA, African
American; hsCRP, high-sensitivity CRP; Ox-LDL, oxidized LDL-C; NEFA, nonesterified fatty acids. *P value fromWilcoxon-Mann-Whitney test for equality ofmeans/
medians or a x2 test for proportions comparing African Americans and whites in the cohort random sample (data not shown).
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but no correlation with nonesterified fatty
acids (P = 0.7). In contrast, IL-18 levels
among African Americans had the stron-
gest correlation with nonesterified fatty
acids (P, 0.001) and a weaker correlation
with HDL-C (P = 0.05), oxidized LDL (P =
0.04), and TGs (P = 0.02). For inflamma-
tory markers, IL-18 had a highly statisti-
cally significant correlation with IL-6
(P, 0.001), CRP (P, 0.001), intercellular
adhesion molecule–1 (P , 0.001), and
complement 3 (C3; P , 0.001) among
whites and a highly significant correlation
only with intercellular adhesion molecule–
1 (P , 0.001) among African Americans.
Although IL-18 levels were significantly
correlated with total (P , 0.001) and
HMW (P , 0.001) adiponectin among
whites, no correlation was seen in African
Americans.
CONCLUSIONSdThis is the first
study to look at the association of IL-18
levels with incident diabetes in a racially
heterogeneous population. Two previous
studies have looked at this association in
predominantly white populations (13,14).
In our study, higher IL-18 levels showed
a significant association with incident dia-
betes in the entire study cohort and in
whites, but not in African Americans.
Upon adjustment for clinical risk factors
associated with diabetes, including age,
parental history of diabetes, BMI, SBP,
and WHR, this association almost reached
statistical significance. Further addition of
fasting glucose and inflammation score to
the models weakened the independent as-
sociation of IL-18 levels with incident
Table 2dDistribution of baseline IL-18 levels in the cohort random sample by race and sex
African Americans Whites
P value*n Mean (SD) Median (IQR) n Mean (SD) Median (IQR)
All 295 209.2 (106.1) 190.6 (116.4) 335 258.2 (139.2) 235.6 (129.7) ,0.001
Women 211 206.7 (106.0) 187.9 (119.9) 206 247.0 (155.8) 225.7 (122.6) ,0.001
Men 84 215.5 (106.6) 203.6 (106.7) 129 276.3 (105.8) 255.1 (117.4) ,0.001
IL-18 levels are in pg/mL. IQR, interquartile range. *Wilcoxon signed-rank test of differences between African American and white participants.
Table 3dHRs for developing diabetes by quartiles of IL-18 stratified by race
Models
Quartiles of IL-18 P value for
trend
P value for
interactionQ1 Q2 Q3 Q4
African Americans
Nondiabetic/diabetic (n) 92/99 59/66 43/57 34/38
IL-18 [median (range)] 129 (13–170) 199 (171–229) 255 (230–297) 356 (299–729)
Whites
Nondiabetic/diabetic (n) 69/38 78/47 81/89 80/114
IL-18 [median (range)] 142 (13–171) 202 (171–230) 264 (231–297) 367 (298–2021)
Model 1
African Americans 1.00 1.01 (0.67–1.53) 1.20 (0.77–1.87) 1.02 (0.62–1.68) 0.86
Whites 1.00 1.11 (0.66–1.87) 1.94 (1.20–3.14) 2.51 (1.57–4.01) ,0.001
Model 2 0.01
African Americans 1.00 1.01 (0.66–1.55) 1.19 (0.76–1.85) 1.01 (0.61–1.66) 0.89
Whites 1.00 1.0 (0.59–1.70) 1.70 (1.04–2.79) 2.10 (1.29–3.41) 0.002
Model 3 0.15
African Americans 1.00 1.03 (0.66–1.59) 1.18 (0.72–1.95) 1.02 (0.61–1.72) 0.93
Whites 1.00 0.66 (0.37–1.20) 1.31 (0.76–2.27) 1.16 (0.68–2.00) 0.07
Model 3.1
African Americans 1.00 1.02 (0.65–1.6) 1.1 (0.67–1.87) 1.05 (0.62–1.79) 0.97
Whites 1.00 0.65 (0.36–1.2) 1.26 (0.72–2.2) 1.13 (0.64–2.0) 0.11
Model 4 0.06
African Americans 1.00 0.66 (0.39–1.12) 1.30 (0.81–2.09) 0.70 (0.38–1.29) 0.09
Whites 1.00 0.67 (0.35–1.28) 0.99 (0.53–1.86) 1.01 (0.55–1.86) 0.41
Model 5 0.17
African Americans 1.00 1.02 (0.66–1.59) 1.17 (0.71–1.94) 1.01 (0.59–1.71) 0.94
Whites 1.00 0.58 (0.32–1.07) 1.04 (0.59–1.84) 0.96 (0.56–1.67) 0.18
Model 6 0.13
African Americans 1.00 0.92 (0.59–1.44) 1.17 (0.71–1.92) 0.94 (0.55–1.59) 0.84
Whites 1.00 0.63 (0.35–1.16) 1.24 (0.70–2.17) 1.10 (0.64–1.89) 0.10
Data are presented as HR (95% CI). Model 1: crude model; Model 2: adjusted for age, sex, center, and race; Model 3 (clinical model): Model 2+ adjusted for parental
history of diabetes, BMI, SBP, andWHR;Model 3.1:Model 2+ adjusted for physical activity, education level, and smoking status;Model 4 (biochemical model): Model
3+ adjusted for glucose, HDL-C, and total TGs;Model 5 (inflammatorymarkermodel):Model 3+ adjusted for inflammation score; Model 6 (anti-inflammatorymarker
model): Model 3+ adjusted for total and HMW adiponectin. Interaction models did not include center as a covariate due to unbalanced cells with regard to race.
Boldface signifies statistical significance.
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diabetes in our study. The exact role of IL-
18 in causation of diabetes is not clear. The
findings of our study support the hypoth-
esis that elevated fasting glucose may itself
be a regulator of IL-18 levels. This is con-
sistent with the other studies showing that
persistent hyperglycemia upregulates the
synthesis of IL-18 and other proinflam-
matory cytokines (19). Hyperglycemia
can lead to oxidative stress and membrane
lipid peroxidation. It has been shown that
the degree of lipid peroxidation is directly
proportional to blood glucose concentra-
tions (20). Persistent oxidative stress indu-
ces stress-sensitive signaling pathways,
such as nuclear factor ofk light polypeptide
gene enhancer in B cells (NF-kB). NF-kB
is a transcription factor that plays a major
role in mediating inflammatory responses
and in the production of proinflammatory
cytokines like IL-6, TNF-a, and IL-18.
The inflammatory cytokines in turn lead
to insulin resistance and overt diabetes
(21), further increasing the plasma glu-
cose levels. This leads to a vicious cascade
phenomenon with a positive-feedback
loop, causing difficulty in determining
whether fasting glucose is upstream or
downstream of IL-18 in the pathway for
onset of diabetes.
It is plausible that both impaired
fasting glucose and elevated IL-18 levels
are drivers of the proinflammatory pathway
culminating in diabetes. This hypothesis is
further strengthened by our observation
that elevated IL-18 levels were not associ-
ated with incident diabetes independent of
inflammatorymarkers including IL-6, CRP,
sialic acid, and orosomucoid. This is con-
sistent with previous reports showing that
IL-18 induces production of TNF-a, IL-6,
and CRP (22). In another model in our
study, addition of HDL-C and TGs weak-
ened the association of IL-18 with incident
diabetes. Because IL-18 is a proinflamma-
tory molecule, further adjustments with
lipid parameters associated with inflamma-
tion may have resulted in overadjustment
and weakening of the independent associa-
tion of IL-18 with incident diabetes.
IL-18 levels showed a weak associa-
tion with incident diabetes when adjusted
for plasma adiponectin levels in our study.
This is consistent with previous studies
showing that future risk of diabetes was
associated with lower levels of total and
HMW adiponectin (13). It may imply that
though a greater amount of IL-18 is pro-
duced in tissues outside the adipose tissue
(23), adipositymaydrive the IL-18produc-
tion in later stages. This is supported by a
significant, but weak, correlation of IL-18
levels with total and HMW adiponectin
levels as well as obesity in the white sub-
group of our study. In their study in a
white female population, Hivert et al.
(13) showed an association of IL-18 levels
with incident diabetes independent of
HMW adiponectin and BMI. The authors,
however, did not adjust the models for
fasting glucose, inflammatory markers,
and lipid parameters, all relevant factors
in the occurrence of diabetes. The study
also showed that the association of IL-18
with diabetes tends to be stronger in
women with lower BMI, suggesting that
increasing adiposity masks the association
of IL-18 with diabetes (13).
Our second aim was to evaluate racial
differences in IL-18 levels and their asso-
ciation with incident diabetes. We found
significantly lower baseline levels of IL-18
in African Americans compared with
whites. It is possible that the difference in
mean IL-18 levels between races is attribut-
able at least in part to genetic and anthro-
pometric differences.
In addition, IL-18 levels were mod-
erately associated with incident diabetes
in whites but not at all in African Amer-
icans. There was a significant interaction
between IL-18 and race in their associa-
tions with incident diabetes. However, this
interaction was attenuated on adjustment
for parental history of diabetes, BMI, SBP,
andWHR. The reason for this interaction is
not known. Duncan et al. (4) found an asso-
ciation of low-grade inflammation with di-
abetes inwhites butnot inAfricanAmericans
in the ARIC cohort. It is well known that
white cell counts differ inAfricanAmericans
compared with whites (24). These find-
ings suggest racial differences in inflam-
matory burden, triggering factors for
inflammatory pathways, and the associa-
tion of inflammation with diabetes.
Interestingly, in our study, IL-18 levels
were correlated strongly with anthropo-
metricmeasures related to obesity inwhites
but not in African Americans. IL-18 levels
have been inconsistently associated with
BMI and body fat in various studies, raising
the question ofwhether themajor source of
IL-18 is not adipose tissue but muscle and
liver. However, the absolute lack of corre-
lation of IL-18 with either BMI or WHR in
African Americans in our study is both a
novel and interesting finding. Moreover,
there was no correlation of adiponectin
with IL-18 levels in African Americans, but
therewas a significant correlation inwhites,
again raising questions regarding the differ-
ence in the source of inflammatorymarkers
and adipocytokines in the two races.
Similarly, fasting glucose and insulin levels
were correlated with IL-18 levels in whites
but not in African Americans, whereas free
fatty acids were correlated with IL-18 levels
in African Americans and not in whites.
Although African Americans have
long been recognized to have different
characteristics of the metabolic syndrome
compared with whites (low TG, high
HDL-C, and high glucose) and increased
frequency of incident diabetes, only more
recently has there been an appreciation of
the differences in inflammation markers
associated with cardiometabolic risk.
African Americans have lower WBC count,
IL-18, fetuin-A, CC chemokine ligand–5,
and regulated on activation, normal T-cell
expressed, and secreted (RANTES) (25)
than whites, but have higher levels of
CRP, sialic acid, fibrinogen, C3, and IL-6
than whites in the ARIC cohort. There is
growing evidence that markers of inflam-
mationmay have ethnic and genetic differ-
ences (24,26). Such differences are also
seen in the association of these inflamma-
tory markers with incident diabetes (4).
One possible explanation for the racial dif-
ferences in levels of various chemokines
and inflammatory markers may be the
polymorphism in the Duffy antigen recep-
tor for chemokines (Darc) (27). Darc is a
blood group alloantigen and serves as a
vascular reservoir of proinflammatory
cytokines. Thedifference in theWBC count
in African Americans compared with
whites is due to the common African-
derived null variant of the Darc gene (28).
By abolishing the expression of Darc on
erythrocytes, the Duffy null variant may al-
ter the concentration and distribution of
chemokines in the blood (27). The null
variant provides selective advantage
against malaria in these populations.
The relation of these inflammatory
markers to the pathophysiology of dia-
betes is unknown. Evolutionary diver-
sity along with associated social and
environmental factors may contribute
to the variable association of diabetes
with insulin resistance, markers of in-
flammation, and anthropometric param-
eters in different races (29). However,
these novel markers of inflammation
and their association with incident dia-
betes need further validation.
Our study has several strengths. The
study cohort is derived from a large well-
studied population based in four different
U.S. communities, suitably designed to
study racial differences and provide a long
prospective follow-up of incident cases of
diabetes (15).
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Limitations
Markers of inflammation are usually sta-
ble in frozen samples, but this has not
been studied over a prolonged period of
time. In this study, we used a single
baseline measurement of IL-18. Whether
obtaining multiple measurements over
time would have strengthened the asso-
ciation seen in the study is unknown.
Summary
Elevated IL-18 levels are associated with
incident diabetes mellitus (DM), but there
is a racial heterogeneity in this associa-
tion. This may imply racial differences in
the pathogenetic pathways of develop-
ment of DM. Further studies are needed
to elucidate the details of this mechanism
of DM and the potential interplay of racial
differences, anthropometric characteris-
tics, and inflammation.
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